Zymes' Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson's Disease

Zymes' Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson's Disease

Hasbrouck Heights, N.J., May, 2010 - Scientists from Zymes LLC, the University of Windsor (Ontario, Canada) and the National Research Council of Canada presented their research at the 2010 Experimental Biology meetings in Anaheim California on April 28th.  The paper entitled, "Protection of SNpc neurons by water soluble CoQ10 in a paraquat induced rat model of Parkinson's disease: The role of neurotrophic factors," describes a potential treatment for halting the progression of Parkinson's disease in an animal model using Zymes' water soluble CoQ10 (WS-CoQ10) formulation.

Parkinson's disease (PD) is a neurodegenerative disorder that results from the progressive loss of select neurons in the brain.  Many studies show that mitochondrial dysfunction/oxidative stress is a major contributor to this disease.  An established animal model of paraquat-induced Parkinson's disease was used in this study.  Animals were given Zymes' water soluble CoQ10 in their drinking water with access 24 hours a day pre-treatment (prophylactic) and post-treatment (therapeutic). In these studies, Zymes' water soluble CoQ10 provided significant protection of dopaminergic neurons and a decrease in symptoms.

"We are very excited about these early stage findings that support the use of Zymes' water soluble CoQ10 to halt the symptoms of Parkinson's disease." said Dr. Shelley Weinstock, Sr. VP of Research and Scientific Affairs.  In addition, in these studies, animals were exposed to the water soluble CoQ10 on a continuous basis in their water, suggesting that small doses, several times a day is a more effective method of administration than larger doses once or twice per day.  More research is needed to determine if Zymes' water soluble CoQ10 may be effective in halting the progression of Parkinson's disease in people.

About Zymes LLC:
Zymes LLC is a bioscience company based in Hasbrouck Heights, NJ that provides innovative solutions to its partners and consumers through proprietary science and technology, enabling new products to enhance the well-being of people. For more information please visit www.zymes.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.